A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells

References

• Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res.93, 189–234 (2005).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol.2, 293–299 (2001).
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol.16, 143–150 (2004).
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol. Lett.100, 7–13 (2005).
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother.54, 721–728 (2005).
   PubMed Web of Science ®Google Scholar
• Marsman M, Jordens I, Griekspoor A, Neefjes J. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis. Adv. Cancer Res.93, 129–158 (2005).
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, van Duinen SG, Tsujisaki M, Ferrone S. Class II HLA antigens in benign and malignant lesions of melanocytic origin. In: HLA Class II Antigens: A Comprehensive Review of Structure and Function. Solheim BG, Moller E, Ferrone S (Eds). Springer-Verlag, Berlin Germany 429–441 (1986).
   Google Scholar
• Brocker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J. Invest. Dermatol.82, 244–247 (1984).
   PubMed Web of Science ®Google Scholar
• Brocker EB, Suter L, Bruggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int. J. Cancer36, 29–35 (1985).
   PubMed Web of Science ®Google Scholar
• Natali P, Bigotti A, Cavaliere R, Liao SK, Taniguchi M, Matsui M, Ferrone S. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res.45, 2883–2889 (1985).
   PubMed Web of Science ®Google Scholar
• Fossati G, Anichini A, Taramelli D et al Immune response to autologous human melanoma: implication of class I and II MHC products. Biochim. Biophys. Acta.865, 235–251 (1986).
   PubMedGoogle Scholar
• D’Alessandro G, Zardawi I, Grace J, McCarthy WH, Hersey P. Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma. Pathology19, 339–346 (1987).
   PubMed Web of Science ®Google Scholar
• Natali PG, Bigotti A, Cavaliere R, Ruiter DJ, Ferrone S. HLA class II antigens synthesized by melanoma cells. Cancer Rev.9, 1–33 (1987).
   Google Scholar
• Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S. Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J. Immunol.138, 1310–1316 (1987).
   PubMed Web of Science ®Google Scholar
• Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp. Clin. Immunogenet.5, 203–212 (1988).
   PubMedGoogle Scholar
• Maio M, Gulwani B, Tombesi S et al. Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-10. J. Immunol.141, 913–920 (1988).
   PubMed Web of Science ®Google Scholar
• van Duinen SG, Ruiter DJ, Broecker EB et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res.48, 1019–1025 (1988).
   PubMed Web of Science ®Google Scholar
• van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expression of HLA-DR, DQ and DP antigens in primary and metastatic melanoma. J. Invest. Dermatol.90, 755–760 (1988).
   PubMed Web of Science ®Google Scholar
• Zaloudik J, Moore M, Ghosh AK, Mechl Z, Rejthar A. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J. Clin. Pathol.41, 1078–1084 (1988).
   PubMed Web of Science ®Google Scholar
• Maio M, Gulwani B, Langer JA et al. Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res.49, 2980–2987 (1989).
   PubMed Web of Science ®Google Scholar
• Maio M, Gulwani B, Morgano A, Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int. J. Cancer44, 554–559 (1989).
   PubMed Web of Science ®Google Scholar
• Natali PG, Bigotti A, Nicotra MR et al. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res.49, 1269–1274 (1989).
   PubMed Web of Science ®Google Scholar
• West KP, Priyakumar P, Jagjivan R, Colloby PS. Can HLA-DR expression help in the routine diagnosis of malignant melanomas? Br. J. Dermatol.121, 175–178 (1989).
   PubMed Web of Science ®Google Scholar
• Elder DE, Rodeck U, Thurin J et al. Antigenic profile of tumor progression states in human melanocytic nevi and melanomas. Cancer Res.49, 5091–5096 (1989).
   PubMed Web of Science ®Google Scholar
• Berdowska I. Cysteine proteases as disease markers. Clin. Chim. Acta.342, 41–69 (2004).
   PubMed Web of Science ®Google Scholar
• Creswell P (Guest Ed.). Antigen processing and presentation. Immunol. Rev.207, 5–313 (2005).
   PubMed Web of Science ®Google Scholar
• Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol.5, 793–806 (2005).
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Sem. Cancer Biol.2, 35–45 (1991).
   PubMedGoogle Scholar
• Wollina U, Kilian U, Henkel U, Schaarschmidt H, Knopf B. The initial steps of tumor progression in melanocytic lineages: a histochemical approach. Anticancer Res.11, 1405–1414 (1991).
   PubMed Web of Science ®Google Scholar
• Colloby PS, West KP, Fletcher A. Is poor prognosis really related to HLA-DR expression by malignant melanoma cells? Histopathology20, 411–416 (1992).
   PubMed Web of Science ®Google Scholar
• Barnhill RL. Pathology and prognostic factors. Curr. Opin. Oncol.5, 364–376 (1993).
   PubMedGoogle Scholar
• Si Z, Hersey P. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int. J. Cancer54, 37–43 (1993).
   PubMed Web of Science ®Google Scholar
• Moretti S, Pinzi C, Berti E et al. In situ expression of transforming growth factor β is associated with melanoma progression and correlates with Ki67, HLA-DR and β 3 integrin expression. Melanoma Res.7, 313–321 (1997).
   PubMed Web of Science ®Google Scholar
• Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer85, 2391–2399 (1999).
   PubMed Web of Science ®Google Scholar
• Ostmeier H, Fuchs B, Otto F et al. Prognostic immunohistochemical markers of primary human melanomas. Br. J. Dermatol.145, 203–209 (2001).
   PubMed Web of Science ®Google Scholar
• Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur. J. Surg. Oncol.27, 88–93 (2001).
   PubMedGoogle Scholar
• Altomonte M, Fonsatti E, Visintin A, Maio M. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene22, 6564–6569 (2003).
   PubMed Web of Science ®Google Scholar
• Bernsen MR, Hakansson L, Gustafsson B et al. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br. J. Cancer88, 424–431 (2003).
   PubMed Web of Science ®Google Scholar
• Marks MS, Theos AC, Raposo G. Melanosomes and MHC class II antigen-processing compartments: a tinted view of intracellular trafficking and immunity. Immunol. Res.27, 409–426 (2003).
   PubMed Web of Science ®Google Scholar
• Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol.13, 45–51 (2001).
   PubMed Web of Science ®Google Scholar
• Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res.44, 4679–4687 (1984).
   PubMed Web of Science ®Google Scholar
• Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol.2, 401–409 (2002).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst.94, 805–818 (2002).
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr. Opin. Immunol.17, 638–642 (2005).
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol. Immunother.54, 1153–1161 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu X, Bavari S, Ulrich R et al. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Eur. J. Immunol.27, 1933–1941 (1997).
   PubMed Web of Science ®Google Scholar
• Igarashi M, Imberti L, Maio M et al. Preparation, Characterization and utilization of monoclonal antibodies to gene products of the hla-d region, with special emphasis on those to polymorphic determinants. In: HLA Class II Antigens: A Comprehensive Review of Structure and Function. Solheim BG, Moller E, Ferrone S (Eds). Springer-Verlag, Berlin, Germany 224–248 (1986).
   Google Scholar
• Chan JKC. Advances in immunohistochemistry: impact on surgical pathology practice. Semin. Diagn. Pathol.17, 170–177 (2000).
   PubMed Web of Science ®Google Scholar
• Dabbs DJ. Diagnostic Immunohistochemistry. Churchill Livingstone, Elsevier Science (2002).
   Google Scholar
• Wilson BS, Herzig MA, Lloyd RV. Immunoperoxidase staining for Ia-like antigens in paraffin-embedded tissues from human melanoma and lung carcinoma. Am. J. Pathol.115, 102–108 (1984).
   PubMed Web of Science ®Google Scholar
• Giacomini P, Tecce R, Nicotra MR, Cohen BB, Mazzilli MC, Natali PG. mAb KUL/05 identifies a denaturation-resistant determinant shared by class II MHC products DR, DQ and DP. J. Immunogenet.16, 203–216 (1989).
   PubMedGoogle Scholar
• Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J. Immunol. Methods.161, 239–256 (1993).
   PubMed Web of Science ®Google Scholar
• Garrido F, Cabrera T, Accolla RS et al. HLA and cancer: 12th International Histocompatibility Workshop study. In: Genetic Diversity of HLA. Functional and Medical Implication. Proc. Twelfth International Histocompatibility Workshop and Conference. Volume. II. Charron D (Ed.). EDK, Sevres, France 445–452 (1997).
   Google Scholar
• Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Downregulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol.154, 745–754 (1999).
   PubMed Web of Science ®Google Scholar
• Campoli M, Cheney R, Rebmann V et al. HLA antigen changes and cancer: A report from the 13th International Histocompatibility Workshop. In: “HLA 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress Volume II. Hansen J, Dupont B (Eds). IHWG Press, WA, USA 445–452 (2004).
   Google Scholar
• Tarnok A, Gerstner AO. Clinical applications of laser scanning cytometry. Cytometry50, 133–143 (2002).
   PubMedGoogle Scholar
• Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J. Invest. Dermatol.100, 239S–244S (1993).
   PubMed Web of Science ®Google Scholar
• Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum. Immunol.63, 444–451 (2002).
   PubMed Web of Science ®Google Scholar
• Radosevich M, Ono SJ. Novel mechanisms of class II major histocompatibility complex gene regulation. Immunol. Res.27, 85–106 (2003).
   PubMed Web of Science ®Google Scholar
• Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in uveal melanoma cells. Invest. Ophthalmol. Vis. Sci.45, 3185–3195 (2004).
   PubMed Web of Science ®Google Scholar
• Matsui M, Temponi M, Ferrone S. Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J. Immunol.139, 2088–2095 (1987).
   PubMed Web of Science ®Google Scholar
• Bene L, Bodnar A, Damjanovich S et al. Membrane topography of HLA I, HLA II, and ICAM-1 is affected by IFN-γ in lipid rafts of uveal melanomas. Biochem. Biophys. Res. Commun.322, 678–683 (2004).
   PubMed Web of Science ®Google Scholar
• Sarkar S, Glassy MC, Ferrone S, Jones OW. Cell cycle and the differential expression of HLA-A,B and HLA-DR antigens on human B lymphoid cells. Proc. Natl Acad. Sci. USA77, 7297–7301 (1980).
   PubMed Web of Science ®Google Scholar
• Ericsson C, Seregard S, Bartolazzi A et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest. Ophthalmol. Vis. Sci.42, 2153–2156 (2001).
   PubMed Web of Science ®Google Scholar
• Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis.20, 105–125 (2004).
   PubMedGoogle Scholar
• Cabrera T, Ruiz-Cabello F, Garrido F. Biological implications of HLA-DR expression in tumours. Scand. J. Immunol.41, 398–406 (1995).
   PubMed Web of Science ®Google Scholar
• Lazaris AC, Theodoropoulos GE, Davaris PS et al. Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer. Dis. Colon Rectum38, 739–745 (1995).
   PubMed Web of Science ®Google Scholar
• Markovic-Lipkovski J, Brasanac D, Todorovic V, Muller CA, Muller GA. Immunomorphological characteristics of renal cell carcinoma. Histol. Histopathol.10, 651–659 (1995).
   PubMed Web of Science ®Google Scholar
• Morita M, Tanaka K, Kawanishi H et al. Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features. J. Surg. Oncol.59, 233–238 (1995).
   PubMed Web of Science ®Google Scholar
• Ricci G, Colombo C, Ghiazza B, Porta C, Moroni M, Illeni MT. HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects. Cancer Lett.98, 121–125 (1995).
   PubMed Web of Science ®Google Scholar
• Rompel R, Petres J, Kaupert K, Muller-Eckhardt G. Human leukocyte antigens and multiple basal cell carcinomas. Recent Results Cancer Res.139, 297–302 (1995).
   PubMedGoogle Scholar
• Ohmori T, Okada K, Arita N, Watanabe Y, Miyazaki T, Tabei R. Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol. Histopathol.10, 789–794 (1995).
   PubMed Web of Science ®Google Scholar
• Rockett JC, Darnton SJ, Crocker J, Matthews HR, Morris AG. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J. Clin. Pathol.48, 539–544 (1995).
   PubMed Web of Science ®Google Scholar
• Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today21, 455–464 (2000).
   PubMedGoogle Scholar
• Ioachim E, Charchanti A, Stavropoulos NE, Skopelitou A, Athanassiou ED, Agnantis NJ. Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma. Histol. Histopathol.15, 721–727 (2000).
   PubMed Web of Science ®Google Scholar
• Bustin SA, Li SR, Phillips S, Dorudi S. Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumor Biol.22, 294–298 (2001).
   PubMedGoogle Scholar
• Ishigami S, Natsugoe S, Tokuda K et al. Invariant chain expression in gastric cancer. Cancer Lett.168, 87–91 (2001).
   PubMed Web of Science ®Google Scholar
• Le YS, Kim TE, Kim BK et al. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp. Mol. Med.34, 18–26 (2002).
   PubMed Web of Science ®Google Scholar
• Lovig T, Andersen SN, Thorstensen L et al. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br. J. Cancer87, 756–762 (2002).
   PubMed Web of Science ®Google Scholar
• Shabtai M, Ye H, Frischer Z, Martin J, Waltzer WC, Malinowski K. Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes. J. Urol.168, 2216–2219 (2002).
   PubMed Web of Science ®Google Scholar
• Chil A, Sikorski M, Bobek M, Jakiel G, Marcinkiewicz J. Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix. Acta. Obstet. Gynecol. Scand.82, 1146–1152 (2003).
   PubMed Web of Science ®Google Scholar
• Tamiolakis D, Kotini A, Venizelos J, Jivannakis T, Simopoulos C, Papadopoulos N. Prognostic significance of HLA-DR antigen in serous ovarian tumors. Clin. Exp. Med.3, 113–118 (2003).
   PubMed Web of Science ®Google Scholar
• Rangel LB, Agarwal R, Sherman-Baust CA, et al. Anomalous expression of the HLA-DR α and β chains in ovarian and other cancers. Cancer Biol. Ther.3, 1021–1027 (2004).
   PubMed Web of Science ®Google Scholar
• Matoba K, Iizuka N, Gondo T et al. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int. J. Cancer115, 231–240 (2005).
   PubMed Web of Science ®Google Scholar
• Schoniger-Hekele M, Hanel S, Wrba F, Muller C. Hepatocellular carcinoma – survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int.25, 62–69 (2005).
   PubMed Web of Science ®Google Scholar
• Drexler HG, Gignac SM, Brenner MK, Coustan-Smith E, Janossy G, Hoffbrand AV. Differential expression of MHC class II antigens in chronic B-cell disorders. Clin. Exp. Immunol.71, 217–223 (1988).
   PubMed Web of Science ®Google Scholar
• Lecchi M, Lovisone E, Genetta C, Peruccio D, Resegotti L, Richiardi P. Gamma-IFN induces a differential expression of HLA-DR, DQ and DP antigens on peripheral blood myeloid leukemic blasts at various stages of differentiation. Leuk. Res.13, 221–226 (1989).
   PubMed Web of Science ®Google Scholar
• Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology98, 296–302 (1999).
   PubMed Web of Science ®Google Scholar
• Nistico P, Tecce R, Giacomini P et al. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res.50, 7422–7429 (1990).
   PubMed Web of Science ®Google Scholar
• Young AN, Amin MB, Moreno CS et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol.158, 1639–1651 (2001).
   PubMed Web of Science ®Google Scholar
• Tamori Y, Tan X, Nakagawa K et al. Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncol. Rep.14, 873–877 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang Z, Xu M, Savas L, LeClair P, Banner BF. Invariant chain expression in colon neoplasms. Virchows Arch.435, 32–36 (1999).
   PubMed Web of Science ®Google Scholar
• Armstrong TD, Clements VK, Ostrand-Rosenberg S. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J. Immunother.21, 218–224 (1998).
   PubMed Web of Science ®Google Scholar
• Deffrennes V, Vedrenne J, Stolzenberg MC et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol.167, 98–106 (2001).
   PubMed Web of Science ®Google Scholar
• Goodwin BL, Xi H, Tejiram R et al. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ.12, 327–335 (2001).
   PubMedGoogle Scholar
• Yazawa T, Kamma H, Fujiwara M et al. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J. Pathol.187, 191–199 (1999).
   PubMed Web of Science ®Google Scholar
• Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-γ inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J. Immunol.156, 2495–2502 (1996).
   PubMed Web of Science ®Google Scholar
• Sartoris SM, Valle T, Barbaro AD et al. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J. Immunol.161, 814–820 (1998).
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M, Schreiber RD. The IFN γ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol.15, 563–591 (1997).
   PubMed Web of Science ®Google Scholar
• Bosshart H, Jarrett RF. Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin’s disease tumor cells. Blood92, 2252–2259 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev.18, 345–357 (1999).
   PubMed Web of Science ®Google Scholar
• Obiri NI, Siegel JP, Varricchio F, Puri RK. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol.95, 148–155 (1994).
   PubMed Web of Science ®Google Scholar
• Baton F, Deruyffelaere C, Chapin M et al. Class II transactivator (CIITA) isoform expression and activity in melanoma. Melanoma Res.14, 453–461 (2004).
   PubMed Web of Science ®Google Scholar
• van der Stoep N, Biesta P, Quinten E, van den Elsen PJ. Lack of IFN-γ-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int. J. Cancer97, 501–507 (2002).
   PubMed Web of Science ®Google Scholar
• Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G. Evidence for retinoblastoma protein (RB) dependent and independent IFN-γ responses: RB coordinately rescues IFN-γ induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene9, 1015–1019 (1994).
   PubMed Web of Science ®Google Scholar
• Yazawa T, Ito T, Kamma H et al. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am. J. Pathol.161, 291–300 (2002).
   PubMed Web of Science ®Google Scholar
• Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene22, 3087–3091 (2003).
   PubMed Web of Science ®Google Scholar
• Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene7, 2315–2321 (1992).
   PubMed Web of Science ®Google Scholar
• Vassiliadis S, Papamatheakis J. The p21ras protein as an intermediate signaling molecule in the IL-4-induced HLA-DR expression on normal and leukemic human myeloid cells. Cell. Immunol.142, 426–433 (1992).
   PubMed Web of Science ®Google Scholar
• Wong CW, Fan YS, Chan TL et al. Cancer Genome Project. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J. Clin. Pathol.58, 640–644 (2005).
   PubMed Web of Science ®Google Scholar
• Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol.14, 301–331 (1996).
   PubMed Web of Science ®Google Scholar
• van den Elsen PJ, van der SN, Vietor HE, Wilson L, van Zutphen M, Gobin SJ. Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-γ inducible promoter (PIV) of CIITA. Hum. Immunol.61, 850–862 (2000).
   PubMed Web of Science ®Google Scholar
• Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, Tokino T et al. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J. Immunol.170, 4980–4985 (2003).
   PubMed Web of Science ®Google Scholar
• Satoh A, Toyota M, Ikeda H et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene23, 8876–8886 (2004).
   PubMed Web of Science ®Google Scholar
• Chou SD, Khan AN, Magner WJ, Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int. Immunol.17, 1483–1494 (2005).
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Toyota M, Satoh A et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-γ in haematopoietic tumour cells. Br. J. Cancer90, 844–852 (2004).
   PubMed Web of Science ®Google Scholar
• Takamura Y, Ikeda H, Kanaseki T et al. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia45, 392–405 (2004).
   PubMed Web of Science ®Google Scholar
• Abril E, Real LM, Serrano A et al. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol. Immunother.47, 113–120 (1998).
   PubMed Web of Science ®Google Scholar
• Boudny V, Dusek L, Adamkova L et al. Lack of STAT 1 phosphorylation at TYR 701 by IFN γ correlates with disease outcome in melanoma patients. Neoplasma52, 330–337 (2005).
   PubMed Web of Science ®Google Scholar
• Prigione I, Corrias MV, Airoldi I et al. Immunogenicity of human neuroblastoma. Ann. NY Acad. Sci.1028, 69–80 (2004).
   Google Scholar
• Holling TM, Schooten E, Langerak AW, van den Elsen PJ. Regulation of MHC class II expression in human T-cell malignancies. Blood103, 1438–1444 (2004).
   PubMed Web of Science ®Google Scholar
• Silacci P, Mottet A, Steimle V, Reith W, Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med.180, 1329–1336 (1994).
   PubMed Web of Science ®Google Scholar
• Jordanova ES, Philippo K, Giphart MJ, Schuuring E, Kluin PM. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics55, 203–209 (2003).
   PubMed Web of Science ®Google Scholar
• Whiteside T, Campoli M, Ferrone S. Tumor induced immune suppression mechanisms and possible solutions. In: Analyzing T Cell Responses. How to Analyze Cellular Immune Responses Against Tumor Associated Antigens. Nagorsen D, Marincola FM (Eds). Springer-Verlag, Netherlands 43–81 (2005).
   Google Scholar
• Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother.50, 3–15 (2001).
   PubMed Web of Science ®Google Scholar
• Altomonte M, Pucillo C, Damante G, Maio M. Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-α by the EBV-B lymphoblastoid cell line JY. J. Immunol.151, 5115–5122 (1993).
   PubMed Web of Science ®Google Scholar
• Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev.24, 195–222 (2005).
   PubMed Web of Science ®Google Scholar
• Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res.18, 150–159 (2005).
   PubMedGoogle Scholar
• Aoudjit F, Guo W, Gagnon-Houde JV et al. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp. Cell. Res.299, 79–90 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso SR, Ortiz P, Pollan M et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol.164, 193–203 (2004).
   PubMed Web of Science ®Google Scholar
• Sisk TJ, Gourley T, Roys S, Chang CH. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J. Immunol.165, 2511–2517 (2000).
   PubMed Web of Science ®Google Scholar
• Zhu XS, Ting JP. A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of γ interferon-mediated suppression of collagen α(2)(I) and other promoters. Mol. Cell. Biol.21, 7078–7088 (2001).
   PubMed Web of Science ®Google Scholar
• Gourley TS, Chang CH. The class II transactivator prevents activation-induced cell death by inhibiting fas ligand gene expression. J. Immunol.166, 2917–2921 (2001).
   PubMed Web of Science ®Google Scholar
• Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class II transactivator. J. Immunol.169, 5078–5088 (2002).
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity11, 263–270 (1999).
   PubMed Web of Science ®Google Scholar